Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0R6JV
|
||||
| Former ID |
DIB000702
|
||||
| Drug Name |
CX-1739
|
||||
| Synonyms |
CX-1739 (injectable/AMPAKINE, respiratory depression); CX-717 follow-on compound (AMPAKINE), Cortex Pharmaceuticals; CX-1739 (injectable/AMPAKINE, respiratory depression), Biovail Laboratories; CX-1739 (injectable/AMPAKINE, respiratory depression), Cortex Pharmaceuticals; CX-1739 (injectable/AMPAKINE, respiratory depression), Valeant
|
||||
| Indication | Attention deficit hyperactivity disorder [ICD9: 314; ICD10:F90] | Phase 2 | [1] | ||
| Company |
Cortex Pharmaceuticals Inc
|
||||
| Target and Pathway | |||||
| Target(s) | Glutamate receptor AMPA subtype | Target Info | Agonist | [2] | |
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028722) | ||||
| REF 2 | AMPAKINE enhancement of social interaction in the BTBR mouse model of autism. Neuropharmacology. 2013 Jan;64:268-82. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.